Browsing by Author Loi, Sherene

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2016Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscapeBeith, Jane; Bell, Richard; Burslem, Katie; de Boer, Richard; Loi, Sherene; McCarthy, Nicole; Redfern, Andrew; Woodward, Natasha; Central Clinical School: MedicineHormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape, Asia-Pacific Journal of Clinical Oncology, vol.12, Suppl.1, 2016,pp 3-18
2013Research Resource: Nuclear Receptors as Transcriptome: Discriminant and Prognostic Value in Breast CancerByth Wilson, Karen; Clarke, Christine; Graham, Justine (Dinny); Kuczek, Elizabeth; Clyne, Colin; Davis, Melissa; Eriksson, Natalie A; Fuller, Peter; Funder, John; Jindal, Shalini; Leedman, Peter J.; Loi, Sherene; Muscat, George E. O.; Ragan, Mark; Simpson, Evan; Tilley, Wayne; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead)Research Resource: Nuclear Receptors as Transcriptome: Discriminant and Prognostic Value in Breast Cancer, Molecular Endocrinology, vol.27, 2, 2013,pp 350-365
2016Serum human epidermal growth factor 2 extracellular domain as a predictive biomarker for lapatinib treatment efficacy in patients with advanced breast cancerDavies, Lucy; Gebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Marschner, Ian; Simes, Robert John; Cameron, David; de Souza, Paul; Di Leo, Angelo; Ellis, Catherine; Geyer, Charles; Johnston, Stephen; Loi, Sherene; Press, Michael F.; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreSerum human epidermal growth factor 2 extracellular domain as a predictive biomarker for lapatinib treatment efficacy in patients with advanced breast cancer, Journal of Clinical Oncology, vol.34, 9, 2016,pp 936-944